The Full Library

Tirzepatide Alcohol Reduction Trial: Can Adding AOD-9604 Improve Liver Fat and Metabolic Health in Heavy Drinkers?

Heavy alcohol use harms metabolic health. A trial testing tirzepatide for alcohol reduction raises the question: could adding the peptide AOD-9604 further

How AOD-9604 Could Fill the Fat-Loss Gap When Insurance Denies GLP-1 Coverage

When insurers deny coverage for tirzepatide or semaglutide, AOD-9604 emerges as a research peptide with a distinct fat-loss mechanism. This article

Tirzepatide Withdrawal and Weight Regain: Why a MOTS-c Bridge Strategy Might Protect Mitochondrial Metabolic Memory

Tirzepatide withdrawal often triggers weight regain as mitochondrial adaptations fade. A MOTS-c bridge strategy may preserve metabolic memory, but

Tirzepatide Prescribing Boom Concerns After FDA Panel Vote: Separating Hype from Metabolic Reality

The FDA panel vote on tirzepatide sparks a prescribing boom, but metabolic science reveals gaps between approved drugs and unregulated peptides like

Tirzepatide and Menstrual Cycle Disruption: What GLP-1 Research Reveals

Tirzepatide and other weight loss peptides may cause menstrual irregularities. This article reviews the limited research on cycle disruption, comparing

AOD-9604 and Tirzepatide Co-Administration: Synergistic Fat Loss or Metabolic Redundancy?

AOD-9604 and tirzepatide target fat loss through different mechanisms, but no studies support their combined use. Regulatory gaps and safety unknowns